Development and Regulatory Meetings. The Parties agree to meet on a quarterly basis or as reasonably requested by the MPP, to review development and filing status and also regarding such reports concerning Licensed Product, Product and/or the Compound. MPP agrees that information contained in quarterly and other such reports shall be treated as Confidential Information of Licensee; provided, however, that such information may be shared with Pfizer (with Pfizer treating such reports as Confidential Information) and that aggregated data may be publicly disclosed by MPP. Licensee shall, at its own expense and using its own resources, and using all due care in accordance with the prevailing standard of professional competence in a regulatory function in the pharmaceutical industry, obtain, maintain and operate in compliance with (a) the Key Approvals and (b) all other authorizations, licenses, permits, registrations, and regulations which may from time to time be required by any Agency for Licensee to import, manufacture, promote, and sell the Licensed Product in the Territory. Licensee will not sell Licensed Product in any country in the Territory prior to obtaining both local health Agency approval or authorization in the country in the Territory where the Licensed Product is sold and Commercialized and relevant approval or authorization for the manufacture of Licensed Product in the country of manufacture. Licensee shall provide quarterly written reports to MPP notifying MPP about the registration process and providing MPP with any other information in this regard that MPP may reasonably require which such reports may be shared with Pfizer (with Pfizer treating such reports as Confidential Information). Licensee shall not transfer, assign, or otherwise convey any of the authorizations, registrations, or permits related to the Licensed Product, as set forth above in this Section 3, to any Affiliate without the prior written notice to MPP and Pfizer.
